Ⅲ期N2非小细胞肺癌的围手术期化疗
Perioperative chemotherapy of stage Ⅲ N2 non-small cell lung cancer
摘要
Ⅲ期N2非小细胞肺癌(NSCLC)占临床就诊肺癌患者的1/3以上,其5年生存率约为15%。从治疗学的观点看,肺癌97国际分期中的ⅢA N2期,是一个异质性非常明显的组合,包括术后才发现纵隔淋巴结镜下转移的N2,也包括了影像学上纵隔淋巴结肿大的单站N2或多站N2,更包括了多站纵隔淋巴结已融合成团的N2。
出处
《中国肺癌杂志》
CAS
2008年第5期652-656,共5页
Chinese Journal of Lung Cancer
参考文献10
-
1O‘Brien ME,Splinter T,Smit EF,et al.Carboplatin and paclitaxel as an induction regimen for patients with biopsy-proven stageⅢA N2non-small cell lung cancer.An EORTC phaseⅡstudy(EORTC08958)[].European Journal of Cancer.2003
-
2Ruebe C,Riesenbeck D,Semik M,et al.Neoadjuvant chemotherapy followed by preoperative radiochemotherapy plus surgery or surgery plus postoperative radiotherapy in stageⅢnon-small cell lung cancer:Results of a randomized phaseⅢtrial of the German Lung CancerCooperative Group[].International Journal of Radiation Oncology Biology Physics.2004
-
3Douillard J,Rosell R,Delena M,et al.Adjuvant vinorelbine plus cispl-atin versus observation in patient with complete resected stageⅠB-ⅢA non-small cell lung cancer[Ajuvant Navelbine International Trialist Association(ANITA)]:a randomized controlled trial[].The Lancet Oncology.2006
-
4Pignon JP,Tribodet H,Scagliotti GV,et al.Lung Adjuvant Cisplatin Evaluation(LACE):a pooled analysis of five randomized clinical trials including4584patients[].Proc Am Soc Clin Onocol.2006
-
5Sofia J,Haddad V,Olaussen KA,et al.Immunohistochemical staining of the Excision Repair Cross-Complementing1(ERCC1)protein as predictor for benefit of adjuvant chemotherapy in the International Lung Cancer(IALT)[].Proceedings of the American Society of Clinical Oncology.2006
-
6Manegold C,Biesma B,Smit H,et al.Docetaxel and cisplatin as induc-tion chemotherapy in stageⅢA N2non-small cell lung cancer:An EORTC phaseⅡtrial(08984)[].Journal of Clinical Oncology.2004
-
7Cappuzzo F,Selvaggi G,Gregorc V,et al.Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stageⅢA bulky N2and stageⅢB non small cell lung carcinoma:An Italian Lung Cancer Project Observational Study[].Cancer.2003
-
8Albain KS,Rusch VW,Crowley JJ,et al.Concurrent cisplatin/etoposide plus chestradiotherapy followed by surgery for stageⅢA(N2)andⅢB non-small-cell lung cancer:Mature results of south west oncology group phaseⅡstudy8805[].Journal of Clinical Oncology.1995
-
9Andre F,Grunenwaid D,Pignon J-P,et al.Survival of Patients With Resected N2Non-Sinail-Cell Lung Cancer:Evidence for a Sube:lassification and Implications[].Journal of Clinical Oncology.2000
-
10Depierre A,Milleron B,Moro-Sibilot D,et al.Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stageⅠ(except T1N0),Ⅱ,andⅢa non-small-cell lung cancer[].Journal of Clinical Oncology.2002
-
1王思愚,谢泽明,洪文善.可切除Ⅲ期N_2非小细胞肺癌治疗共识与争议[J].肿瘤学杂志,2004,10(1):1-4. 被引量:3
-
2王思愚,吴一龙,戎铁华,黄植藩,区伟.Ⅲ期N2非小细胞肺癌的外科治疗[J].中华肿瘤杂志,2002,24(6):605-607. 被引量:24
-
3邹健.对Ⅲ期N2非小细胞肺癌临床分期的思考与质疑[J].中国医药指南,2014,12(17):391-392.
-
4王思愚.不可切除Ⅲ期N_2非小细胞肺癌治疗新模式[J].中国肺癌杂志,2005,8(5):405-407. 被引量:1
-
5陈海平,贺新爱,张继林.影响手术治疗Ⅲ期N_2非小细胞肺癌的生存因素[J].现代医药卫生,2008,24(15):2308-2310. 被引量:1
-
6干尧鳘,张奕,刘泗军,石勇,阚奇伟.Ⅲ期N_2非小细胞肺癌手术治疗预后的影响因素分析[J].川北医学院学报,2008,23(4):347-350. 被引量:4
-
7陈建武,张幸平,曾奕明,张华平,肖华平,肖丽华,苏菁菁.Ⅲa(N_2)期非小细胞肺癌术后放疗疗效分析[J].重庆医科大学学报,2009,34(11):1566-1570. 被引量:7
-
8董志云.肺癌新的国际分期和综合治疗[J].哮喘与肺部疾病,2001(1):41-43.
-
9吴一龙.非小细胞肺癌国际分期的修订[J].癌症,1999,18(1):101-103. 被引量:19
-
10张毅,支修益.非小细胞肺癌术后辅助治疗现状及进展[J].中华临床医师杂志(电子版),2009,3(11):12-14. 被引量:10